Search results
Results from the WOW.Com Content Network
904,000 (2015) [6] Deaths. 60,700 (2015) [7] Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). [2][8] Early on, there are typically no symptoms. [2] Later, non-painful lymph node swelling, feeling tired, fever, night sweats, or weight loss for no clear reason ...
Richter's transformation (RT), also known as Richter's syndrome, is the conversion of chronic lymphocytic leukemia (CLL) or its variant, small lymphocytic lymphoma (SLL), into a new and more aggressively malignant disease. [1] CLL is the circulation of malignant B lymphocytes with or without the infiltration of these cells into lymphatic or ...
Physician, Scientist. Employer. The Feinstein Institute for Medical Research. Known for. Medical Research. Website. [1] Nicholas Chiorazzi is a physician and researcher from the United States. He is the head of the Karches Center for Chronic Lymphocytic Leukemia Research at the Feinstein Institute for Medical Research in Manhasset, New York.
The diagnosis of MBL in these patients depends on finding 0.5-5x10 9 monoclonal B cells that express the makers characteristic of CLL/SLL MLB, atypical CLL/SLL MLB, non-CLL/SLL MLB, or MLB-MZ. [3] However, individuals with CBL-MZ commonly present with B-cell blood counts that are extremely high (>4.0x10 9 ; range 3.0x10 9 /L to 37.1x10 9 /L ...
NK cell leukemia. Aggressive NK-cell leukemia (ANKL) is a lymphoid leukemia that is a deficiency NK cells. Not very much is known about this disease due to its rarity, but it is highly aggressive. A majority of patients with NK cell leukemia die within a year of diagnosis, and for ANKL in particular, half of patients die within two months.
Response evaluation criteria in solid tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment. The criteria were published in February 2000 by an international collaboration including the European Organisation for Research ...
Deletion of 13q14 (del 13q14) is the most common abnormality in CLL with roughly 50% of patients with cells containing this defect. When del 13q14 is seen in isolation, patients have the best prognosis and most will live many years, even decades, without the need for therapy.
Acalabrutinib, sold under the brand name Calquence, is a medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia /small lymphocytic Lymphoma (CLL/SLL). [7] It may be used both in relapsed as well as in treatment-naive settings. [8]